Post-treatment PSA ≤0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques
- 31 December 1999
- journal article
- Published by Elsevier BV in Urology
- Vol. 54 (6), 968-971
- https://doi.org/10.1016/s0090-4295(99)00346-5
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- PROSTATE SPECIFIC ANTIGEN NADIR ACHIEVED BY MEN APPARENTLY CURED OF PROSTATE CANCER BY RADIOTHERAPYJournal of Urology, 1999
- Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidityInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidanceInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Conformal proton therapy for prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directionsInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Results of 3D conformal radiotherapy in the treatment of localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Consensus statement: Guidelines for PSA following radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Radiotherapy for localized prostate carcinomaCancer, 1997
- Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.Journal of Clinical Oncology, 1996
- Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinomaCancer, 1996